ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

COSM13: Otolaryngologists Share Research, Insights at Annual Meetings

by Thomas R. Collins • May 1, 2013

  • Tweet
  • Email
Print-Friendly Version

You Might Also Like

  • COSM14: Genetics Research on Hearing Loss Provides New Insights
  • Combined Otolaryngology Spring Meetings a Forum for Otolaryngologists to Listen, Debate, Network
  • Research Highlights from the 2017 TRIO Annual Meeting
  • Otolaryngologists Gather at COSM for 2016 Triological Society Annual Meeting
Explore This Issue
May 2013


ORLANDO—The Combined Otolaryngology Spring Meetings, held here April 10–14, featured the annual meetings of several otolaryngology organizations, covering topics ranging across ear, nose and throat care. Here are a few highlights from the programs of some of these organizations.

Progress Treating Neurofibromatosis Type 2

American Neurotology Society

Several trials are ongoing and showing some promise in the treatment of neurofibromatosis type 2 (NF2), said Bradley Welling, MD, PhD, chair of otolaryngology-head and neck surgery at Ohio State University’s College of Medicine in Columbus, during his William F. House Lecture at the Annual Spring Meeting of the American Neurotology Society.

Lapatinib, an erbB2/EGF-inhibitor, is being studied in a phase 0 trial, with enrollment nearing a close. Patients will be treated 10 days pre-operatively, and then the tumor will be removed, with the drug concentration and molecular target assessed. That trial is being led by Johns Hopkins, along with Ohio State and other centers.

An earlier phase 2 study found a 15 percent reduction in tumor volume in four of 17 patients and a 10-decibel improvement in hearing in four of 13 (Neuro Oncol. 2012;14:1163-1170).

In the first study of the VEGF-inhibitor bevacizumab in NF2, 13 of 23 showed a hearing response, some with “quite remarkable” improvement, Dr. Welling said (Otol Neurotol. 2012;33:1046-1052). Two Phase 2 trials, which will assess hearing response and radiographic change, are getting underway, he said.

At Ohio State, a phase 1 study of the HDAC-inhibitor AR42 will assess safety. While the study was originally meant to include only liquid tumors, solid tumors, including NF2 patients, have been added. Eighteen patients, five with NF2-related tumors, have been enrolled in the dose-escalation study.

In all, eight drugs are now in trials for NF2, and are critically needed considering that the disorder has a 20-year survival rate of just 38 percent and causes deafness, facial paralysis and stroke. For now, treatment has to take into account the seriousness of the tumors found, along with the patient’s willingness to accept the risk of clinical trials.

Beyond that, the research has some other challenges, Dr. Welling said. He emphasized that the drugs will have to be well-tolerated because they may need to be taken for a lifetime. “How do we define success?” he said. “Certainly, I think if we stop tumor growth, for most of us, we consider that successful. We don’t necessarily have to see the tumor regress. Do we decide based on the effect of the growth on the target? And how sustainable is the treatment?”

Pages: 1 2 3 4 5 | Single Page

Filed Under: Features Tagged With: annual meeting, COSM13, otolaryngologistIssue: May 2013

You Might Also Like:

  • COSM14: Genetics Research on Hearing Loss Provides New Insights
  • Combined Otolaryngology Spring Meetings a Forum for Otolaryngologists to Listen, Debate, Network
  • Research Highlights from the 2017 TRIO Annual Meeting
  • Otolaryngologists Gather at COSM for 2016 Triological Society Annual Meeting

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Weaning Patients Off of PPIs
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.